Sio Gene Therapies Inc. buy tamam
Start price
31.08.17
/
50%
€143.67
Target price
09.01.18
€144.32
Performance (%)
-88.37%
End price
09.01.18
€16.71
Summary
This prediction ended on 09.01.18 with a price of €16.71. Massive losses of -88.37% were the result for the BUY prediction by tamam. tamam has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Sio Gene Therapies Inc. | - | - | - | - |
| iShares Core DAX® | 1.301% | -1.386% | 12.259% | 59.752% |
| iShares Nasdaq 100 | 0.612% | -4.172% | 1.687% | 86.147% |
| iShares Nikkei 225® | 8.772% | 9.777% | 30.041% | 63.047% |
| iShares S&P 500 | 0.254% | -2.301% | 0.794% | 57.981% |
Comments by tamam for this prediction
In the thread Sio Gene Therapies Inc. diskutieren
tamam stimmt der Outperform-Einschätzung der institutionellen Analysten zu
One of the most watched trial results on the horizon is for Intepirdine targeting Alzheimers'. Phase 3 data is out from Axovant Sciences by the end of September. Positive results would trigger a massive rally in the stock. I am not sanguine simply because this disease area has the highest failure rate in the industry.
(Vom Mitglied beendet)